EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis.

The article discusses a clinical trial, NCT06646016, focusing on the use of UVADEX in conjunction with extracorporeal photopheresis (ECP) for immune-related colitis induced by immune checkpoint inhibitor therapy in melanoma or NSCLC patients. The study aims to evaluate the efficacy of this treatment compared to the best available therapy (BAT) for participants with inadequate response to steroids. The trial involves specific outcome measures related to remission of colitis, resolution of symptoms, and survival rates, with a completion date set for February 6, 2026. [Extracted from the article]